A Phase 2 interventional study of LDE225 0.75% and Vehicle in Sporadic Superficial and Nodular Skin Basal Cell Carcinomas, sponsored by Novartis Pharmaceuticals. Terminated at 4 sites in 2 countries. Open to participants aged 18 Years to 75 Years. Per ClinicalTrials.gov, last updated 2015-10-30.
Sponsored by Novartis Pharmaceuticals (part of Novartis) · Phase 2, Interventional, and Treatment
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
Among 18 studies in Carcinoma, Basal Cell with a site in Australia — 1 open to participants now, 2 under way, none of them phase 3. Carcinoma, Basal Cell · Australia.
Among the 18 studies in Carcinoma, Basal Cell with a site in Australia, this one is the 14th largest by enrollment of the 17 interventional ones that give a count, is one of 2 that started in 2009, is one of 10 in phase 2, and was the 7th registered.
389 studies on the registry are indexed under Carcinoma, Basal Cell; 69 are open to participants now.
Browse Carcinoma, Basal Cell studies →1 of the 18 studies in Carcinoma, Basal Cell with a site in Australia is open now. Recruiting first, the newest first:
Melanoma Institute Australia · Sites in Australia
Ages 18+
A study can be open while its sites in Australia have not opened yet or have stopped. Only those recruiting at a site in Australia →
Of the 52 Carcinoma, Basal Cell studies recruiting now, 48 (92%) set no upper age limit and none (0%) stop at 75 or younger; 9 take children under 18; 2 take healthy volunteers.
This study: 18 Years to 75 Years · all sexes · no healthy volunteers.
The full table on the hub →This tab as a report to print or save as PDF → With an account.
18 studies; the count open now beside each. This study's row is marked.
A study in two phases is counted once above. Listed by phase, each with its combined phases: Phase 1 4 · Phase 2 11 · Phase 3 3
First in 2000; this study’s year is marked. 2 started in 2009.
By drug class, each counting the studies that test any of its medicines:
This study's enrollment of 25 is below the median of 50 across 272 interventional studies indexed under Carcinoma, Basal Cell.
Median enrollment 75 across the 17 interventional studies, 1,000 across the 1 observational. Of the 16 that completed or were terminated, 8 (50%) have results posted.
This tab as a report to print or save as PDF → With an account.
16 of 18 have an industry lead sponsor. The 10 most frequent:
This study is registered under Novartis Pharmaceuticals, one of the names counted as Novartis. Under that name alone:
Novartis Pharmaceuticals is the lead sponsor of 2,719 studies on the registry; 222 are open to participants now.
Of its 585 completed or terminated interventional studies of FDA-regulated products, 439 (75%) have results posted.
Novartis has 8 studies filed under Carcinoma, Basal Cell — fewer than ten, so there is no comparison to draw.
1 of the studies in Carcinoma, Basal Cell with a site in Australia that are under way reach primary completion within a year, 0 of them phase 3. Phase 3 first, then by date:
| Study | Primary completion |
|---|---|
| NCT06536257Melanoma Institute AustraliaPersonalised Immunotherapy Platform | 2027-06-01 |
Add it to your calendar (.ics) → With an account.
Among the 18 studies in Carcinoma, Basal Cell with a site in Australia, from their registry updates:
This tab as a report to print or save as PDF → With an account.
This was a double-blinded, randomized, vehicle-controlled study in sporadic superficial BCC (sBCC) and nodular BCC (nBCC) patients which consisted of a 21-day screening period, a treatment period of 6 weeks (topical 0.75% LDE225 cream application b.i.d) ending with post treatment biopsies, as safety visit one week after final study drug administration (Day 50), a visit on Day 83 for excision of the treated BCC, and an end of study evaluation (Day 90).
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
Exclusion Criteria:
Other protocol defined Incl./Excl. criteria may apply.
Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
The diagnosis was confirmed by looking at a sample under a microscope: tissue from a biopsy or surgery (histology), or cells from a fluid or needle sample (cytology).
Your pathology report is the document that shows this.
Histologically or cytologically confirmed
The diagnosis was confirmed by looking at a sample under a microscope: tissue from a biopsy or surgery (histology), or cells from a fluid or needle sample (cytology).
Your pathology report is the document that shows this.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Participants topically applied 0.75% LDE225 cream twice daily for 6 weeks.
Drug: LDE225 0.75%
Participants topically applied matching placebo cream twice daily for 6 weeks.
Drug: Vehicle
0.75% cream
matching placebo cream to 0.75% LDE225 cream
Clinical Evaluation of sBCCs Tumors
The clinical response parameters were defined as (i) complete response (i.e., there is no longer any visible evidence of a lesion consistent with BCC at this site), (ii) partial response (i.e., although a BCC still remains at this site, it has demonstrated a visible decrease in size compared with baseline), and (iii) no response / worsening (i.e., the BCC has not demonstrated any visible decrease in size compared with baseline).
Time frame: Day 43
Twenty-five participants were enrolled into the trial. However, one participant was excluded from the efficacy analysis. Therefore, the enrollment number differs from the number started below.
| Milestone | LDE225 0.75% | Vehicle |
|---|---|---|
| Started | 16 | 8 |
| Completed | 15 | 8 |
| Not completed | 1 | 0 |
| Withdrew: Withdrawal by subject | 1 | 0 |
The clinical response parameters were defined as (i) complete response (i.e., there is no longer any visible evidence of a lesion consistent with BCC at this site), (ii) partial response (i.e., although a BCC still remains at this site, it has demonstrated a visible decrease in size compared with baseline), and (iii) no response / worsening (i.e., the BCC has not demonstrated any visible decrease in size compared with baseline).
| Participants | LDE225 0.75% | Vehicle |
|---|---|---|
| Complete response | 3 | 1 |
| Partial response | 9 | 4 |
| No response | 4 | 3 |
Non-serious events are listed at a 5% frequency threshold.
| Group | Deaths | Serious | Other |
|---|---|---|---|
| LDE225 0.75% - sBCC | — | 0/16 (0%) | 8/16 (50%) |
| Vehicle - sBCC | — | 0/8 (0%) | 5/8 (62.5%) |
| LDE225 0.75% - nBCC | — | 0/1 (0%) | 1/1 (100%) |
| Event | LDE225 0.75% - sBCC | Vehicle - sBCC | LDE225 0.75% - nBCC |
|---|---|---|---|
| DiarrhoeaGastrointestinal disorders | 0/16 | 0/8 | 1/1 |
| Body temperature increasedInvestigations | 0/16 | 0/8 | 1/1 |
| HeadacheNervous system disorders | 0/16 | 1/8 | 1/1 |
| Application site dermatitisGeneral disorders | 0/16 | 1/8 | 0/1 |
| Application site pruritusGeneral disorders | 0/16 | 1/8 | 0/1 |
| Acute tonsillitisInfections and infestations | 0/16 | 1/8 | 0/1 |
| Gastrointestinal infectionInfections and infestations | 2/16 | 0/8 | 0/1 |
| Oral herpesInfections and infestations | 0/16 | 1/8 | 0/1 |
| Blood creatinine increasedInvestigations | 0/16 | 1/8 | 0/1 |
| Blood glucose increasedInvestigations | 0/16 | 1/8 | 0/1 |
| Age, Continuous(Years) | LDE225 0.75% | Vehicle | Total |
|---|---|---|---|
| Mean | 63 ± 7.3 | 63 ± 7.5 | 63 ± 7.4 |
| Sex: Female, Male(Participants) | LDE225 0.75% | Vehicle | Total |
|---|---|---|---|
| Female | 4 | 4 | 8 |
| Male | 12 | 4 | 16 |
The record gives a start of Dec 2009, a primary completion of Feb 2011 and a completion of Feb 2011. It does not say whether these dates are actual or estimated.
Results were first posted in Oct 2015, 4 years 8 months after primary completion.
How these figures are worked out, and which studies are left out of them.
This study is terminated, as verified in Oct 2015. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Studies of the drug tested here: Sonidegib